Fig. 4From: Development of an Interpretable Deep Learning Model for Pathological Tumor Response Assessment After Neoadjuvant TherapyThe correlation between pCR, MPR, yTNM and the benefit of survival. Both pCR and MPR were predictive of a longer OS and PFS (a-d). Regarding the well-accepted assessment metric yTNM, patients with a lower yTNM stage were also shown having a greater likelihood of obtaining better survival benefits as well (e–f). (pCR: the absence of viable residual tumor; MPR: less than or equal to 10% of the viable residual tumor. yTNM implied the features of the primary tumor(T), regional lymph nodes(N) and the presence or absence of distant metastasis(M) based on post-therapy findings; OS: overall survival; PFS: progression-free survival)Back to article page